 Slobodan Todorovic
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcium Channels, T-Type | 68 | 2025 | 105 | 20.180 |
Why?
| | Calcium Channel Blockers | 31 | 2025 | 165 | 5.750 |
Why?
| | Thalamus | 13 | 2025 | 126 | 4.640 |
Why?
| | Isoflurane | 15 | 2025 | 41 | 4.530 |
Why?
| | Neurons | 27 | 2025 | 1642 | 4.450 |
Why?
| | Hypnotics and Sedatives | 13 | 2025 | 216 | 3.510 |
Why?
| | Pain | 19 | 2022 | 782 | 3.340 |
Why?
| | Analgesics | 16 | 2025 | 231 | 3.130 |
Why?
| | Rats, Sprague-Dawley | 53 | 2025 | 2540 | 3.010 |
Why?
| | Nociceptors | 19 | 2021 | 41 | 3.010 |
Why?
| | Pregnanolone | 6 | 2025 | 35 | 2.830 |
Why?
| | Anesthetics | 12 | 2023 | 99 | 2.770 |
Why?
| | Analgesia | 4 | 2024 | 105 | 2.770 |
Why?
| | Ganglia, Spinal | 25 | 2018 | 89 | 2.750 |
Why?
| | Anesthetics, Inhalation | 8 | 2026 | 52 | 2.660 |
Why?
| | Androstanols | 7 | 2022 | 30 | 2.500 |
Why?
| | Nitriles | 11 | 2022 | 205 | 2.480 |
Why?
| | Rats | 61 | 2025 | 5614 | 2.420 |
Why?
| | Hyperalgesia | 15 | 2022 | 131 | 2.420 |
Why?
| | Diabetic Neuropathies | 10 | 2021 | 100 | 2.260 |
Why?
| | Action Potentials | 13 | 2022 | 507 | 2.100 |
Why?
| | Neurons, Afferent | 14 | 2008 | 102 | 2.050 |
Why?
| | Calcium Channels, R-Type | 4 | 2025 | 5 | 2.000 |
Why?
| | Sensory Receptor Cells | 10 | 2018 | 101 | 1.990 |
Why?
| | Animals | 107 | 2026 | 38111 | 1.970 |
Why?
| | Anesthesia | 4 | 2023 | 258 | 1.880 |
Why?
| | Hippocampus | 14 | 2026 | 967 | 1.710 |
Why?
| | Neuralgia | 9 | 2021 | 146 | 1.690 |
Why?
| | Anesthetics, General | 6 | 2022 | 14 | 1.680 |
Why?
| | Intralaminar Thalamic Nuclei | 5 | 2019 | 21 | 1.680 |
Why?
| | Membrane Potentials | 19 | 2022 | 280 | 1.640 |
Why?
| | Anesthesia, General | 4 | 2019 | 118 | 1.480 |
Why?
| | Nitrous Oxide | 7 | 2019 | 35 | 1.470 |
Why?
| | Presynaptic Terminals | 4 | 2015 | 86 | 1.400 |
Why?
| | Calcium Channels | 9 | 2022 | 154 | 1.350 |
Why?
| | Synaptic Transmission | 9 | 2022 | 291 | 1.340 |
Why?
| | Ion Channel Gating | 7 | 2013 | 92 | 1.290 |
Why?
| | Steroids | 8 | 2025 | 160 | 1.270 |
Why?
| | Mice, Knockout | 17 | 2025 | 3125 | 1.220 |
Why?
| | Cerebral Cortex | 4 | 2021 | 465 | 1.210 |
Why?
| | Patch-Clamp Techniques | 14 | 2025 | 289 | 1.160 |
Why?
| | Hypnosis | 2 | 2025 | 12 | 1.130 |
Why?
| | Thioctic Acid | 3 | 2021 | 12 | 1.110 |
Why?
| | Mice | 31 | 2026 | 18366 | 1.060 |
Why?
| | Ventral Thalamic Nuclei | 2 | 2019 | 5 | 1.040 |
Why?
| | Mice, Inbred C57BL | 20 | 2026 | 5997 | 1.040 |
Why?
| | Brain | 11 | 2023 | 2941 | 1.020 |
Why?
| | Inhibitory Postsynaptic Potentials | 5 | 2020 | 48 | 1.010 |
Why?
| | Oxidation-Reduction | 13 | 2015 | 1087 | 0.920 |
Why?
| | Delta Rhythm | 1 | 2025 | 3 | 0.900 |
Why?
| | Neuronal Plasticity | 4 | 2023 | 309 | 0.880 |
Why?
| | Theta Rhythm | 1 | 2025 | 18 | 0.880 |
Why?
| | Somatosensory Cortex | 1 | 2025 | 42 | 0.850 |
Why?
| | Dose-Response Relationship, Drug | 18 | 2021 | 2032 | 0.830 |
Why?
| | Conditioning, Classical | 1 | 2025 | 120 | 0.830 |
Why?
| | Glycerides | 1 | 2024 | 17 | 0.820 |
Why?
| | Arachidonic Acids | 1 | 2024 | 43 | 0.810 |
Why?
| | Neural Pathways | 5 | 2015 | 311 | 0.800 |
Why?
| | Calcium | 10 | 2022 | 1184 | 0.800 |
Why?
| | Cysteine | 9 | 2022 | 210 | 0.780 |
Why?
| | Endocannabinoids | 1 | 2024 | 57 | 0.770 |
Why?
| | Neural Inhibition | 3 | 2018 | 178 | 0.760 |
Why?
| | Benzamides | 3 | 2020 | 224 | 0.750 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 621 | 0.750 |
Why?
| | Cation Transport Proteins | 2 | 2022 | 118 | 0.740 |
Why?
| | Electroencephalography | 6 | 2025 | 551 | 0.730 |
Why?
| | Pregnanediones | 7 | 2026 | 12 | 0.730 |
Why?
| | Male | 46 | 2026 | 72416 | 0.710 |
Why?
| | Peripheral Nerves | 3 | 2014 | 72 | 0.710 |
Why?
| | Fear | 1 | 2025 | 366 | 0.690 |
Why?
| | Immobility Response, Tonic | 1 | 2021 | 5 | 0.690 |
Why?
| | Nociception | 3 | 2022 | 17 | 0.680 |
Why?
| | Electrocorticography | 1 | 2021 | 20 | 0.670 |
Why?
| | Brain Waves | 1 | 2021 | 45 | 0.650 |
Why?
| | Long-Term Potentiation | 2 | 2019 | 200 | 0.610 |
Why?
| | Surgical Wound | 1 | 2019 | 27 | 0.600 |
Why?
| | Excitatory Postsynaptic Potentials | 4 | 2019 | 117 | 0.600 |
Why?
| | Female | 49 | 2025 | 78387 | 0.580 |
Why?
| | In Vitro Techniques | 11 | 2015 | 1048 | 0.580 |
Why?
| | Ion Channels | 4 | 2015 | 129 | 0.570 |
Why?
| | Spinal Cord | 2 | 2019 | 382 | 0.570 |
Why?
| | Receptors, GABA-A | 6 | 2022 | 138 | 0.560 |
Why?
| | Adenosine Triphosphate | 3 | 2019 | 498 | 0.530 |
Why?
| | Pain Threshold | 8 | 2016 | 73 | 0.530 |
Why?
| | Sleep | 1 | 2025 | 901 | 0.530 |
Why?
| | Ventral Tegmental Area | 1 | 2018 | 60 | 0.520 |
Why?
| | Protein Isoforms | 5 | 2022 | 402 | 0.510 |
Why?
| | Pain Measurement | 10 | 2015 | 555 | 0.500 |
Why?
| | Animals, Newborn | 5 | 2026 | 902 | 0.490 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2021 | 198 | 0.480 |
Why?
| | Posterior Horn Cells | 3 | 2012 | 10 | 0.480 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 220 | 0.470 |
Why?
| | Receptors, Purinergic P2X3 | 1 | 2015 | 15 | 0.470 |
Why?
| | Trace Elements | 2 | 2015 | 52 | 0.460 |
Why?
| | Anesthesia, Inhalation | 1 | 2015 | 14 | 0.450 |
Why?
| | Transcription Factor RelA | 1 | 2015 | 85 | 0.450 |
Why?
| | Sciatic Neuropathy | 4 | 2015 | 32 | 0.450 |
Why?
| | Synaptic Vesicles | 1 | 2015 | 40 | 0.440 |
Why?
| | Electrophysiological Phenomena | 3 | 2025 | 60 | 0.440 |
Why?
| | Anticonvulsants | 4 | 2006 | 242 | 0.420 |
Why?
| | Hot Temperature | 6 | 2018 | 407 | 0.410 |
Why?
| | Cell Line | 10 | 2010 | 2882 | 0.410 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1143 | 0.410 |
Why?
| | S-Nitrosoglutathione | 1 | 2013 | 8 | 0.400 |
Why?
| | HEK293 Cells | 5 | 2022 | 744 | 0.400 |
Why?
| | Axons | 2 | 2013 | 201 | 0.400 |
Why?
| | Pyridines | 1 | 2018 | 605 | 0.390 |
Why?
| | Glycosylation | 1 | 2013 | 172 | 0.380 |
Why?
| | Synapses | 5 | 2026 | 439 | 0.370 |
Why?
| | Skin | 4 | 2021 | 758 | 0.340 |
Why?
| | Epilepsy, Absence | 2 | 2025 | 12 | 0.340 |
Why?
| | Humans | 45 | 2025 | 144981 | 0.330 |
Why?
| | Organ Culture Techniques | 4 | 2021 | 154 | 0.330 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 685 | 0.330 |
Why?
| | Midline Thalamic Nuclei | 1 | 2010 | 3 | 0.320 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 381 | 0.320 |
Why?
| | Recombinant Proteins | 7 | 2015 | 1371 | 0.310 |
Why?
| | 1-Octanol | 1 | 2009 | 1 | 0.310 |
Why?
| | Models, Animal | 3 | 2020 | 392 | 0.310 |
Why?
| | Calcium Signaling | 3 | 2007 | 252 | 0.300 |
Why?
| | Neurotransmitter Agents | 1 | 2009 | 82 | 0.300 |
Why?
| | Peripheral Nervous System Diseases | 3 | 2006 | 133 | 0.300 |
Why?
| | Mibefradil | 2 | 2014 | 9 | 0.300 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2010 | 124 | 0.300 |
Why?
| | Cells, Cultured | 10 | 2013 | 4155 | 0.290 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2016 | 193 | 0.290 |
Why?
| | Electrophysiology | 5 | 2019 | 218 | 0.290 |
Why?
| | Reflex, Righting | 2 | 2025 | 15 | 0.290 |
Why?
| | Inhibitory Concentration 50 | 4 | 2011 | 91 | 0.280 |
Why?
| | Enflurane | 2 | 2005 | 4 | 0.280 |
Why?
| | Neuroprotective Agents | 3 | 2007 | 143 | 0.280 |
Why?
| | Protein Kinase C | 1 | 2009 | 252 | 0.280 |
Why?
| | Reducing Agents | 1 | 2007 | 4 | 0.270 |
Why?
| | S-Nitrosothiols | 1 | 2007 | 5 | 0.260 |
Why?
| | Time Factors | 6 | 2025 | 7184 | 0.250 |
Why?
| | Peripheral Nervous System | 1 | 2006 | 20 | 0.250 |
Why?
| | Calcium Channels, L-Type | 2 | 2025 | 118 | 0.250 |
Why?
| | Fatty Acids | 1 | 2010 | 452 | 0.250 |
Why?
| | Ketamine | 3 | 2022 | 133 | 0.250 |
Why?
| | Piperidines | 2 | 2020 | 217 | 0.240 |
Why?
| | Ascorbic Acid | 1 | 2007 | 180 | 0.240 |
Why?
| | Methyl Ethers | 1 | 2026 | 19 | 0.240 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2015 | 228 | 0.230 |
Why?
| | Postoperative Complications | 1 | 2018 | 2920 | 0.230 |
Why?
| | Electric Stimulation | 3 | 2015 | 276 | 0.230 |
Why?
| | Behavior, Animal | 3 | 2021 | 520 | 0.230 |
Why?
| | Transfection | 4 | 2013 | 940 | 0.230 |
Why?
| | Disease Models, Animal | 9 | 2022 | 4569 | 0.220 |
Why?
| | Touch | 2 | 2005 | 40 | 0.220 |
Why?
| | Up-Regulation | 1 | 2008 | 852 | 0.220 |
Why?
| | Models, Neurological | 3 | 2015 | 254 | 0.220 |
Why?
| | Injections, Intraperitoneal | 2 | 2021 | 117 | 0.220 |
Why?
| | Antioxidants | 2 | 2021 | 549 | 0.210 |
Why?
| | Central Nervous System | 1 | 2006 | 281 | 0.210 |
Why?
| | Zinc | 1 | 2007 | 295 | 0.210 |
Why?
| | Verapamil | 1 | 2004 | 37 | 0.210 |
Why?
| | Gene Silencing | 1 | 2025 | 205 | 0.210 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.210 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.210 |
Why?
| | Isotopes | 1 | 2024 | 34 | 0.210 |
Why?
| | Hydrogen Peroxide | 2 | 2019 | 336 | 0.200 |
Why?
| | Calcium Channels, N-Type | 2 | 2022 | 12 | 0.200 |
Why?
| | Microscopy, Electron | 2 | 2015 | 415 | 0.200 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.200 |
Why?
| | Wakefulness | 1 | 2025 | 169 | 0.200 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2003 | 18 | 0.200 |
Why?
| | Amines | 1 | 2003 | 40 | 0.200 |
Why?
| | Estranes | 4 | 2009 | 4 | 0.190 |
Why?
| | Nerve Net | 2 | 2022 | 285 | 0.190 |
Why?
| | Injections, Spinal | 2 | 2020 | 121 | 0.190 |
Why?
| | Rats, Wistar | 2 | 2017 | 451 | 0.190 |
Why?
| | Sex Characteristics | 2 | 2025 | 791 | 0.190 |
Why?
| | Spatial Memory | 1 | 2022 | 28 | 0.190 |
Why?
| | RNA, Small Interfering | 1 | 2025 | 635 | 0.190 |
Why?
| | Signal Transduction | 3 | 2015 | 5233 | 0.180 |
Why?
| | Neurocognitive Disorders | 1 | 2022 | 33 | 0.180 |
Why?
| | Kinetics | 5 | 2010 | 1629 | 0.180 |
Why?
| | Adjuvants, Anesthesia | 1 | 2021 | 13 | 0.170 |
Why?
| | Isomerism | 1 | 2021 | 57 | 0.170 |
Why?
| | Injections, Intravenous | 1 | 2021 | 200 | 0.170 |
Why?
| | Ion Transport | 1 | 2020 | 63 | 0.160 |
Why?
| | Heart Diseases | 1 | 2004 | 350 | 0.160 |
Why?
| | Rats, Transgenic | 2 | 2018 | 18 | 0.160 |
Why?
| | Propofol | 3 | 2020 | 85 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2004 | 358 | 0.160 |
Why?
| | Autism Spectrum Disorder | 1 | 2026 | 412 | 0.160 |
Why?
| | Symporters | 1 | 2020 | 48 | 0.160 |
Why?
| | Pyramidal Cells | 1 | 2020 | 79 | 0.150 |
Why?
| | Metals | 2 | 2013 | 142 | 0.150 |
Why?
| | Rodentia | 1 | 2020 | 62 | 0.150 |
Why?
| | Molecular Conformation | 1 | 2019 | 148 | 0.150 |
Why?
| | Myasthenic Syndromes, Congenital | 1 | 2019 | 1 | 0.150 |
Why?
| | Histidine | 2 | 2010 | 66 | 0.150 |
Why?
| | Amino Acid Sequence | 3 | 2013 | 2157 | 0.150 |
Why?
| | Dizocilpine Maleate | 2 | 2018 | 24 | 0.150 |
Why?
| | GABA Modulators | 1 | 1998 | 11 | 0.140 |
Why?
| | Nervous System | 2 | 2009 | 70 | 0.140 |
Why?
| | Ubiquitin-Specific Proteases | 1 | 2018 | 4 | 0.140 |
Why?
| | Neuromuscular Junction | 1 | 2019 | 65 | 0.140 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2018 | 108 | 0.140 |
Why?
| | Apoptosis | 2 | 2025 | 2430 | 0.140 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2018 | 21 | 0.140 |
Why?
| | Age Factors | 2 | 2025 | 3335 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2019 | 136 | 0.140 |
Why?
| | Magnesium | 2 | 1998 | 155 | 0.140 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 83 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 196 | 0.130 |
Why?
| | Neurogenesis | 1 | 2019 | 157 | 0.130 |
Why?
| | Receptors, Serotonin | 1 | 1997 | 35 | 0.130 |
Why?
| | Cytosol | 1 | 2018 | 227 | 0.130 |
Why?
| | Muscle Proteins | 1 | 2019 | 244 | 0.130 |
Why?
| | Potassium | 1 | 1997 | 152 | 0.130 |
Why?
| | Receptors, GABA | 2 | 2015 | 13 | 0.120 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2609 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 405 | 0.120 |
Why?
| | Sex Factors | 2 | 2021 | 2115 | 0.120 |
Why?
| | Epilepsy | 2 | 2015 | 387 | 0.120 |
Why?
| | Mice, Obese | 2 | 2013 | 66 | 0.120 |
Why?
| | GABA-A Receptor Agonists | 2 | 2020 | 17 | 0.120 |
Why?
| | TRPV Cation Channels | 1 | 2016 | 43 | 0.120 |
Why?
| | Transient Receptor Potential Channels | 1 | 2015 | 4 | 0.120 |
Why?
| | Metallothionein | 1 | 2015 | 25 | 0.120 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2015 | 18 | 0.110 |
Why?
| | Dopamine | 1 | 2018 | 289 | 0.110 |
Why?
| | Nerve Degeneration | 1 | 2015 | 48 | 0.110 |
Why?
| | Peripheral Nerve Injuries | 1 | 2015 | 38 | 0.110 |
Why?
| | 4-Butyrolactone | 1 | 2015 | 23 | 0.110 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2015 | 39 | 0.110 |
Why?
| | Midazolam | 1 | 2015 | 72 | 0.110 |
Why?
| | Stroke | 1 | 2004 | 1259 | 0.110 |
Why?
| | Analysis of Variance | 3 | 2009 | 1311 | 0.110 |
Why?
| | Drug Synergism | 1 | 2015 | 357 | 0.110 |
Why?
| | Biological Transport | 1 | 2015 | 418 | 0.100 |
Why?
| | Nerve Fibers | 2 | 2013 | 104 | 0.100 |
Why?
| | Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 1 | 2013 | 9 | 0.100 |
Why?
| | Neuraminidase | 1 | 2013 | 25 | 0.100 |
Why?
| | Phenytoin | 3 | 2003 | 21 | 0.100 |
Why?
| | Asparagine | 1 | 2013 | 35 | 0.100 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2012 | 381 | 0.100 |
Why?
| | Dithionitrobenzoic Acid | 2 | 2004 | 3 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 722 | 0.100 |
Why?
| | Sciatic Nerve | 1 | 2013 | 60 | 0.100 |
Why?
| | Barbiturates | 2 | 2005 | 6 | 0.100 |
Why?
| | Catalysis | 1 | 2013 | 322 | 0.090 |
Why?
| | Phosphorylation | 2 | 2019 | 1733 | 0.090 |
Why?
| | Chronic Disease | 2 | 2009 | 1813 | 0.090 |
Why?
| | GTP-Binding Proteins | 2 | 2011 | 153 | 0.090 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2931 | 0.090 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 592 | 0.090 |
Why?
| | Cannabinoid Receptor Modulators | 1 | 2011 | 9 | 0.090 |
Why?
| | Cell Membrane | 1 | 2015 | 706 | 0.090 |
Why?
| | Mice, Transgenic | 2 | 2007 | 2185 | 0.090 |
Why?
| | Arachidonic Acid | 1 | 2011 | 101 | 0.080 |
Why?
| | Antibodies | 1 | 2013 | 403 | 0.080 |
Why?
| | Adrenochrome | 1 | 2010 | 2 | 0.080 |
Why?
| | Pentetic Acid | 1 | 2010 | 12 | 0.080 |
Why?
| | Deferoxamine | 1 | 2010 | 27 | 0.080 |
Why?
| | Salicylates | 1 | 2010 | 29 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2019 | 2832 | 0.080 |
Why?
| | Morphogenesis | 1 | 2011 | 173 | 0.080 |
Why?
| | Catalase | 1 | 2010 | 130 | 0.080 |
Why?
| | Chelating Agents | 1 | 2010 | 73 | 0.080 |
Why?
| | DNA Primers | 1 | 2011 | 512 | 0.080 |
Why?
| | Amnesia | 1 | 2009 | 47 | 0.080 |
Why?
| | Organometallic Compounds | 1 | 2010 | 113 | 0.080 |
Why?
| | Consciousness | 1 | 2009 | 34 | 0.080 |
Why?
| | Anesthetics, Dissociative | 1 | 2009 | 46 | 0.080 |
Why?
| | Anesthetics, Intravenous | 1 | 2009 | 69 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1718 | 0.070 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2009 | 194 | 0.070 |
Why?
| | Afferent Pathways | 1 | 2008 | 46 | 0.070 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 116 | 0.070 |
Why?
| | Nitric Oxide | 1 | 2013 | 897 | 0.070 |
Why?
| | Constriction | 1 | 2008 | 47 | 0.070 |
Why?
| | Molecular Structure | 1 | 2009 | 501 | 0.070 |
Why?
| | Yugoslavia | 2 | 2006 | 4 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 434 | 0.070 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 140 | 0.070 |
Why?
| | Base Sequence | 1 | 2011 | 2191 | 0.070 |
Why?
| | Nickel | 1 | 2008 | 64 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2011 | 319 | 0.060 |
Why?
| | Memory | 1 | 2009 | 296 | 0.060 |
Why?
| | Tetrodotoxin | 1 | 2007 | 40 | 0.060 |
Why?
| | Potassium Channel Blockers | 1 | 2007 | 47 | 0.060 |
Why?
| | Cyclic GMP | 1 | 2007 | 92 | 0.060 |
Why?
| | Catalytic Domain | 1 | 2007 | 234 | 0.060 |
Why?
| | Drug Interactions | 2 | 2005 | 401 | 0.060 |
Why?
| | Myotonic Dystrophy | 1 | 2006 | 10 | 0.060 |
Why?
| | Structure-Activity Relationship | 2 | 2004 | 570 | 0.060 |
Why?
| | Dystrophin | 1 | 2005 | 39 | 0.060 |
Why?
| | Pentobarbital | 1 | 2005 | 17 | 0.060 |
Why?
| | Caspase 3 | 1 | 2026 | 238 | 0.050 |
Why?
| | Etomidate | 1 | 2005 | 18 | 0.050 |
Why?
| | Mitochondria | 1 | 2011 | 984 | 0.050 |
Why?
| | Hemoglobins | 1 | 2007 | 384 | 0.050 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2005 | 91 | 0.050 |
Why?
| | Cerebral Infarction | 1 | 2004 | 47 | 0.050 |
Why?
| | Oxidants | 1 | 2004 | 103 | 0.050 |
Why?
| | Ethosuximide | 1 | 2003 | 2 | 0.050 |
Why?
| | Gene Deletion | 1 | 2005 | 389 | 0.050 |
Why?
| | Carbamazepine | 1 | 2003 | 22 | 0.050 |
Why?
| | Sodium Channel Blockers | 1 | 2003 | 24 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 333 | 0.050 |
Why?
| | Social Behavior | 1 | 2026 | 288 | 0.050 |
Why?
| | Acetates | 1 | 2003 | 80 | 0.050 |
Why?
| | Urban Population | 1 | 2006 | 491 | 0.050 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2022 | 10 | 0.050 |
Why?
| | Hindlimb | 1 | 2003 | 131 | 0.050 |
Why?
| | Physical Stimulation | 1 | 2002 | 68 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2026 | 451 | 0.050 |
Why?
| | Streptozocin | 2 | 2014 | 21 | 0.040 |
Why?
| | Child Welfare | 1 | 2004 | 231 | 0.040 |
Why?
| | Stereoisomerism | 2 | 1998 | 105 | 0.040 |
Why?
| | Dithiothreitol | 1 | 2001 | 19 | 0.040 |
Why?
| | GABA Antagonists | 2 | 2015 | 34 | 0.040 |
Why?
| | omega-Conotoxin GVIA | 2 | 1998 | 5 | 0.040 |
Why?
| | Amiloride | 2 | 1998 | 25 | 0.040 |
Why?
| | Recurrence | 1 | 2004 | 1135 | 0.040 |
Why?
| | Succinimides | 1 | 2000 | 21 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2014 | 11699 | 0.040 |
Why?
| | Thalamic Nuclei | 1 | 2019 | 9 | 0.040 |
Why?
| | Ethanol | 1 | 2005 | 627 | 0.040 |
Why?
| | Neurotoxicity Syndromes | 1 | 2020 | 38 | 0.040 |
Why?
| | Child | 5 | 2022 | 22657 | 0.040 |
Why?
| | Morphine | 1 | 2020 | 171 | 0.040 |
Why?
| | Receptors, Cholinergic | 1 | 2019 | 41 | 0.040 |
Why?
| | Chromaffin Cells | 1 | 1998 | 4 | 0.040 |
Why?
| | Algorithms | 1 | 2007 | 1839 | 0.040 |
Why?
| | omega-Conotoxins | 1 | 1998 | 4 | 0.040 |
Why?
| | Child, Preschool | 3 | 2019 | 11799 | 0.040 |
Why?
| | Phosphates | 1 | 2019 | 180 | 0.040 |
Why?
| | Barium | 1 | 1998 | 27 | 0.040 |
Why?
| | Sodium Channels | 1 | 1998 | 63 | 0.040 |
Why?
| | Neurotoxins | 1 | 1998 | 28 | 0.030 |
Why?
| | N-Methylaspartate | 1 | 1998 | 43 | 0.030 |
Why?
| | Convulsants | 1 | 1998 | 8 | 0.030 |
Why?
| | Thiopental | 1 | 1998 | 13 | 0.030 |
Why?
| | Cations, Divalent | 1 | 1998 | 47 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 145 | 0.030 |
Why?
| | Pedigree | 1 | 2019 | 514 | 0.030 |
Why?
| | Cations | 1 | 1997 | 82 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2019 | 340 | 0.030 |
Why?
| | Prefrontal Cortex | 1 | 2020 | 328 | 0.030 |
Why?
| | Actins | 1 | 2019 | 425 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1490 | 0.030 |
Why?
| | Microtubules | 1 | 2019 | 286 | 0.030 |
Why?
| | Seizures | 1 | 2020 | 477 | 0.030 |
Why?
| | Heart Defects, Congenital | 1 | 2004 | 914 | 0.030 |
Why?
| | Neuronal Apoptosis-Inhibitory Protein | 1 | 2015 | 3 | 0.030 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2015 | 5 | 0.030 |
Why?
| | Serbia | 1 | 2015 | 7 | 0.030 |
Why?
| | Nipecotic Acids | 1 | 2015 | 6 | 0.030 |
Why?
| | Oximes | 1 | 2015 | 26 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2015 | 28 | 0.030 |
Why?
| | Peptides | 2 | 1998 | 998 | 0.030 |
Why?
| | Glutamic Acid | 2 | 2012 | 251 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 183 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2015 | 155 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2004 | 5417 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1998 | 699 | 0.030 |
Why?
| | Mutation | 3 | 2015 | 4099 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 551 | 0.020 |
Why?
| | Infant | 2 | 2006 | 10039 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 536 | 0.020 |
Why?
| | Phenotype | 2 | 2015 | 3164 | 0.020 |
Why?
| | Biophysical Phenomena | 1 | 2012 | 68 | 0.020 |
Why?
| | Prospective Studies | 1 | 2004 | 8000 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2004 | 3870 | 0.020 |
Why?
| | Copper | 1 | 2012 | 113 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 304 | 0.020 |
Why?
| | Glycine | 1 | 2012 | 187 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 10797 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 130 | 0.020 |
Why?
| | Sensory Gating | 1 | 2009 | 44 | 0.020 |
Why?
| | Binding Sites | 1 | 2012 | 1331 | 0.020 |
Why?
| | Reaction Time | 1 | 2009 | 438 | 0.020 |
Why?
| | Cesium | 2 | 1998 | 20 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1619 | 0.020 |
Why?
| | Myotonin-Protein Kinase | 1 | 2006 | 2 | 0.020 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2006 | 26 | 0.020 |
Why?
| | Hospital Records | 1 | 2006 | 10 | 0.020 |
Why?
| | Bicuculline | 1 | 2005 | 18 | 0.010 |
Why?
| | Computer Simulation | 1 | 2010 | 1026 | 0.010 |
Why?
| | Xenopus | 1 | 2005 | 89 | 0.010 |
Why?
| | Genetics, Population | 1 | 2006 | 215 | 0.010 |
Why?
| | Oocytes | 1 | 2005 | 178 | 0.010 |
Why?
| | Exons | 1 | 2005 | 358 | 0.010 |
Why?
| | Adult | 3 | 2019 | 40511 | 0.010 |
Why?
| | Protein Conformation | 1 | 2006 | 946 | 0.010 |
Why?
| | Body Weight | 1 | 2005 | 978 | 0.010 |
Why?
| | Genotype | 1 | 2005 | 1835 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1390 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2883 | 0.010 |
Why?
| | Cycloleucine | 1 | 1998 | 4 | 0.010 |
Why?
| | Kainic Acid | 1 | 1998 | 33 | 0.010 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 1998 | 42 | 0.010 |
Why?
| | Nootropic Agents | 1 | 1998 | 30 | 0.010 |
Why?
| | Propionates | 1 | 1998 | 39 | 0.010 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 1998 | 37 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2507 | 0.010 |
Why?
| | Feedback | 1 | 1998 | 181 | 0.010 |
Why?
| | Choline | 1 | 1998 | 136 | 0.010 |
Why?
| | Receptors, AMPA | 1 | 1998 | 147 | 0.010 |
Why?
| | Necrosis | 1 | 1998 | 244 | 0.010 |
Why?
| | Adolescent | 2 | 2006 | 22453 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2006 | 5873 | 0.010 |
Why?
| | Barium Compounds | 1 | 1994 | 12 | 0.010 |
Why?
| | Nerve Fibers, Myelinated | 1 | 1994 | 47 | 0.010 |
Why?
| | Microelectrodes | 1 | 1994 | 47 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1991 | 0.010 |
Why?
| | Chlorides | 1 | 1994 | 142 | 0.010 |
Why?
| | Middle Aged | 1 | 2006 | 35937 | 0.000 |
Why?
|
|
Todorovic's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|